148 related articles for article (PubMed ID: 33368602)
1. MUC4 is expressed in alveolar rhabdomyosarcoma.
Forgó E; Hornick JL; Charville GW
Histopathology; 2021 May; 78(6):905-908. PubMed ID: 33368602
[TBL] [Abstract][Full Text] [Related]
2. MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement.
Doyle LA; Wang WL; Dal Cin P; Lopez-Terrada D; Mertens F; Lazar AJ; Fletcher CD; Hornick JL
Am J Surg Pathol; 2012 Oct; 36(10):1444-51. PubMed ID: 22982887
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of FOXO1 immunohistochemistry for rhabdomyosarcoma classification.
Rutland CD; Gedallovich J; Wang A; Zdravkovic S; Varma S; Hornick JL; Charville GW
Histopathology; 2023 Jul; 83(1):49-56. PubMed ID: 36860202
[TBL] [Abstract][Full Text] [Related]
4. MUC4 expression in meningiomas: under-recognized immunophenotype particularly in meningothelial and angiomatous subtypes.
Matsuyama A; Jotatsu M; Uchihashi K; Tsuda Y; Shiba E; Haratake J; Hisaoka M
Histopathology; 2019 Jan; 74(2):276-283. PubMed ID: 30112770
[TBL] [Abstract][Full Text] [Related]
5. Recurrent YAP1 and KMT2A Gene Rearrangements in a Subset of MUC4-negative Sclerosing Epithelioid Fibrosarcoma.
Kao YC; Lee JC; Zhang L; Sung YS; Swanson D; Hsieh TH; Liu YR; Agaram NP; Huang HY; Dickson BC; Antonescu CR
Am J Surg Pathol; 2020 Mar; 44(3):368-377. PubMed ID: 31592798
[TBL] [Abstract][Full Text] [Related]
6. MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma.
Doyle LA; Möller E; Dal Cin P; Fletcher CD; Mertens F; Hornick JL
Am J Surg Pathol; 2011 May; 35(5):733-41. PubMed ID: 21415703
[TBL] [Abstract][Full Text] [Related]
7. Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature.
Yasuda T; Perry KD; Nelson M; Bui MM; Nasir A; Goldschmidt R; Gnepp DR; Bridge JA
Hum Pathol; 2009 Mar; 40(3):341-8. PubMed ID: 18973919
[TBL] [Abstract][Full Text] [Related]
8. The Expression of Mucin-4 (MUC4) in Sarcomas Apart From Sclerosing Epithelioid Fibrosarcoma and Low-Grade Fibromyxoid Sarcoma.
Hassan U; Saeed SM; Mushtaq S; Hussain M; Hameed M
Cureus; 2023 Nov; 15(11):e49546. PubMed ID: 38156143
[TBL] [Abstract][Full Text] [Related]
9. ALK protein expression in rhabdomyosarcomas.
Pillay K; Govender D; Chetty R
Histopathology; 2002 Nov; 41(5):461-7. PubMed ID: 12405914
[TBL] [Abstract][Full Text] [Related]
10. Glypican-3 is expressed in rhabdomyosarcomas but not adult spindle cell and pleomorphic sarcomas.
Thway K; Selfe J; Missiaglia E; Fisher C; Shipley J
J Clin Pathol; 2011 Jul; 64(7):587-91. PubMed ID: 21493758
[TBL] [Abstract][Full Text] [Related]
11. Sclerosing rhabdomyosarcoma in adults: report of four cases of a hyalinizing, matrix-rich variant of rhabdomyosarcoma that may be confused with osteosarcoma, chondrosarcoma, or angiosarcoma.
Folpe AL; McKenney JK; Bridge JA; Weiss SW
Am J Surg Pathol; 2002 Sep; 26(9):1175-83. PubMed ID: 12218574
[TBL] [Abstract][Full Text] [Related]
12. [Rhabdomyosarcoma in middle to old-aged patients: analysis of clinicopathological features and prognosis in 76 cases].
Yu L; Wang J
Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):910-6. PubMed ID: 23336377
[TBL] [Abstract][Full Text] [Related]
13. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
[TBL] [Abstract][Full Text] [Related]
14. Low-grade fibromyxoid sarcoma with prominent giant rosettes and heterotopic ossification.
Hisaoka M; Matsuyama A; Aoki T; Sakamoto A; Yokoyama K
Pathol Res Pract; 2012 Sep; 208(9):557-60. PubMed ID: 22819758
[TBL] [Abstract][Full Text] [Related]
15. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Rudzinski ER; Teot LA; Anderson JR; Moore J; Bridge JA; Barr FG; Gastier-Foster JM; Skapek SX; Hawkins DS; Parham DM
Am J Clin Pathol; 2013 Jul; 140(1):82-90. PubMed ID: 23765537
[TBL] [Abstract][Full Text] [Related]
16. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma.
Ganti R; Skapek SX; Zhang J; Fuller CE; Wu J; Billups CA; Breitfeld PP; Dalton JD; Meyer WH; Khoury JD
Mod Pathol; 2006 Sep; 19(9):1213-20. PubMed ID: 16729016
[TBL] [Abstract][Full Text] [Related]
17. A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1-mutant sclerosing are associated with unfavorable outcome.
Owosho AA; Huang SC; Chen S; Kashikar S; Estilo CL; Wolden SL; Wexler LH; Huryn JM; Antonescu CR
Oral Oncol; 2016 Oct; 61():89-97. PubMed ID: 27688110
[TBL] [Abstract][Full Text] [Related]
18. PAX immunoreactivity identifies alveolar rhabdomyosarcoma.
Sullivan LM; Atkins KA; LeGallo RD
Am J Surg Pathol; 2009 May; 33(5):775-80. PubMed ID: 19145202
[TBL] [Abstract][Full Text] [Related]
19. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.
Jothi M; Mal M; Keller C; Mal AK
Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448
[TBL] [Abstract][Full Text] [Related]
20. Soft Tissue Special Issue: Skeletal Muscle Tumors: A Clinicopathological Review.
Kohashi K; Kinoshita I; Oda Y
Head Neck Pathol; 2020 Mar; 14(1):12-20. PubMed ID: 31950473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
